{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:47:31Z","timestamp":1792590451853,"version":"4.5.0"},"reference-count":36,"publisher":"MyJove Corporation","issue":"228","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoVE"],"DOI":"10.3791\/69628","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:02:05Z","timestamp":1772236925000},"source":"Crossref","is-referenced-by-count":0,"title":["Procedures for the Identification of SARS-CoV-2 Entry Inhibitors as Potential Antivirals using MLV-Based Pseudoviruses"],"prefix":"10.3791","author":[{"given":"Andreina","family":"Ayala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lissett","family":"Avecilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Samuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adael\u00e9n","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"de la Guardia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Lleonart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2098","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"869832","DOI":"10.3389\/fcimb.2022.869832","type":"journal-article","article-title":"SARS-CoV-2 and emerging variants: Unmasking structure, function, infection, and immune escape mechanisms","volume":"12","author":"Li","year":"2022","unstructured":"Li, J. et al. SARS-CoV-2 and emerging variants: Unmasking structure, function, infection, and immune escape mechanisms. Front Cell Infect Microbiol. 12, 869832 (2022).","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"ref2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41580-021-00418-x","type":"journal-article","article-title":"Mechanisms of SARS-CoV-2 entry into cells","volume":"23","author":"Jackson","year":"2022","unstructured":"Jackson, C. B., Farzan, M., Chen, B., Choe, H. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol. 23 (1), 3-20 (2022).","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1288686","DOI":"10.3389\/fmolb.2023.1288686","type":"journal-article","article-title":"Structural understanding of SARS-CoV-2 virus entry to host cells","volume":"10","author":"Le","year":"2023","unstructured":"Le, K., Kannappan, S., Kim, T., Lee, J. H., Lee, H.-R., Kim, K. K. Structural understanding of SARS-CoV-2 virus entry to host cells. Front Mol Biosci. 10, 1288686 (2023).","journal-title":"Front Mol Biosci"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"793320","DOI":"10.3389\/fviro.2021.793320","type":"journal-article","article-title":"Improved SARS-CoV-2 spike glycoproteins for pseudotyping lentiviral vectors","volume":"1","author":"Ayoub","year":"2021","unstructured":"Ayoub, P. G. et al. Improved SARS-CoV-2 spike glycoproteins for pseudotyping lentiviral vectors. Front Virol. 1, 793320 (2021).","journal-title":"Front Virol"},{"issue":"7","key":"ref5","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1515\/cclm-2020-0633","type":"journal-article","article-title":"Biosafety measures for preventing infection from COVID-19 in clinical laboratories:IFCC Taskforce Recommendations","volume":"58","author":"Lippi","year":"2020","unstructured":"Lippi, G. et al. Biosafety measures for preventing infection from COVID-19 in clinical laboratories:IFCC Taskforce Recommendations. Clin Chem Lab Med. 58 (7), 1053-1062 (2020).","journal-title":"Clin Chem Lab Med"},{"issue":"1","key":"ref6","doi-asserted-by":"crossref","first-page":"17966","DOI":"10.1038\/s41598-022-22921-7","type":"journal-article","article-title":"A pseudovirus-based platform to measure neutralizing antibodies in Mexico using SARS-CoV-2 as proof-of-concept","volume":"12","author":"Cruz-Cardenas","year":"2022","unstructured":"Cruz-Cardenas, J. A. et al. A pseudovirus-based platform to measure neutralizing antibodies in Mexico using SARS-CoV-2 as proof-of-concept. Sci Rep. 12 (1), 17966 (2022).","journal-title":"Sci Rep"},{"issue":"1","key":"ref7","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3390\/biom15010135","type":"journal-article","article-title":"Pseudotyped viruses: A useful platform for pre-clinical studies conducted in a BSL-2 laboratory setting","volume":"15","author":"Rizatdinova","year":"2025","unstructured":"Rizatdinova, S. N., Ershova, A. E., Astrakhantseva, I. V. Pseudotyped viruses: A useful platform for pre-clinical studies conducted in a BSL-2 laboratory setting. Biomolecules. 15 (1), 135 (2025).","journal-title":"Biomolecules"},{"issue":"23","key":"ref8","doi-asserted-by":"crossref","first-page":"e2035","DOI":"10.21769\/BioProtoc.2035","type":"journal-article","article-title":"Murine leukemia virus (MLV)-based coronavirus spike-pseudotyped particle production and infection","volume":"6","author":"Millet","year":"2016","unstructured":"Millet, J. K., Whittaker, G. R. Murine leukemia virus (MLV)-based coronavirus spike-pseudotyped particle production and infection. Bio Protoc. 6 (23), e2035 (2016).","journal-title":"Bio Protoc"},{"issue":"145","key":"ref9","first-page":"e59010","type":"journal-article","article-title":"Production of pseudotyped particles to study highly pathogenic coronaviruses in a biosafety level 2 setting","author":"Millet","year":"2019","unstructured":"Millet, J. K. et al. Production of pseudotyped particles to study highly pathogenic coronaviruses in a biosafety level 2 setting. J Vis Exp. 145, e59010 (2019).","journal-title":"J Vis Exp"},{"issue":"4","key":"ref10","doi-asserted-by":"crossref","first-page":"100818","DOI":"10.1016\/j.xpro.2021.100818","type":"journal-article","article-title":"Application of pseudotyped virus particles to monitor Ebola virus and SARS-CoV-2 viral entry in human cell lines","volume":"2","author":"Eichler","year":"2021","unstructured":"Eichler, M., Aksi, E., Pfeilschifter, J., Imre, G. Application of pseudotyped virus particles to monitor Ebola virus and SARS-CoV-2 viral entry in human cell lines. STAR Protoc. 2 (4), 100818 (2021).","journal-title":"STAR Protoc"},{"issue":"1","key":"ref11","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1038\/s41598-024-52177-2","type":"journal-article","article-title":"Development of a pseudo-typed virus particle based method to determine the efficacy of virucidal agents","volume":"14","author":"Thomas","year":"2024","unstructured":"Thomas, J. et al. Development of a pseudo-typed virus particle based method to determine the efficacy of virucidal agents. Sci Rep. 14 (1), 2174 (2024).","journal-title":"Sci Rep"},{"issue":"3","key":"ref12","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/cpch.25","type":"journal-article","article-title":"Optimized PEI-based transfection method for transient transfection and lentiviral production:PEI-based transfection for lentiviral production","volume":"9","author":"Yang","year":"2017","unstructured":"Yang, S., Zhou, X., Li, R., Fu, X., Sun, P. Optimized PEI-based transfection method for transient transfection and lentiviral production:PEI-based transfection for lentiviral production. Curr Protoc Chem Biol. 9 (3), 147-157 (2017).","journal-title":"Curr Protoc Chem Biol"},{"issue":"1","key":"ref13","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/s41467-020-14957-y","type":"journal-article","article-title":"Extracellular nanovesicles for packaging of CRISPR-Cas9 protein and sgRNA to induce therapeutic exon skipping","volume":"11","author":"Gee","year":"2020","unstructured":"Gee, P. et al. Extracellular nanovesicles for packaging of CRISPR-Cas9 protein and sgRNA to induce therapeutic exon skipping. Nat Commun. 11 (1), 1334 (2020).","journal-title":"Nat Commun"},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3390\/mps1010008","type":"journal-article","article-title":"Pseudotype neutralization assays:From laboratory bench to data analysis","volume":"1","author":"Ferrara","year":"2018","unstructured":"Ferrara, F., Temperton, N. Pseudotype neutralization assays:From laboratory bench to data analysis. Methods Protoc. 1 (1), 8 (2018).","journal-title":"Methods Protoc"},{"issue":"4","key":"ref15","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/nar\/23.4.628","type":"journal-article","article-title":"A transient three-plasmid expression system for the production of high titer retroviral vectors","volume":"23","author":"Soneoka","year":"1995","unstructured":"Soneoka, Y. et al. A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res. 23 (4), 628-633 (1995).","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"ref16","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1021\/bp049865x","type":"journal-article","article-title":"Transduction efficiency of pantropic retroviral vectors is controlled by the envelope plasmid to vector plasmid ratio","volume":"21","author":"Chen","year":"2005","unstructured":"Chen, Y., Miller, W. M., Aiyar, A. Transduction efficiency of pantropic retroviral vectors is controlled by the envelope plasmid to vector plasmid ratio. Biotechnol Prog. 21 (1), 274-282 (2005).","journal-title":"Biotechnol Prog"},{"issue":"2","key":"ref17","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/108705719900400206","type":"journal-article","article-title":"A simple statistical parameter for use in evaluation and validation of high throughput screening assays","volume":"4","author":"Zhang","year":"1999","unstructured":"Zhang, J. H., Chung, T. D., Oldenburg, K. R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen. 4 (2), 67-73 (1999).","journal-title":"J Biomol Screen"},{"issue":"4","key":"ref18","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1128\/JVI.72.4.3155-3160.1998","type":"journal-article","article-title":"Characterization of Ebola virus entry by using pseudotyped viruses:Identification of receptor-deficient cell lines","volume":"72","author":"Wool-Lewis","year":"1998","unstructured":"Wool-Lewis, R. J., Bates, P. Characterization of Ebola virus entry by using pseudotyped viruses:Identification of receptor-deficient cell lines. J Virol. 72 (4), 3155-3160 (1998).","journal-title":"J Virol"},{"issue":"17","key":"ref19","doi-asserted-by":"crossref","first-page":"9007","DOI":"10.1128\/JVI.78.17.9007-9015.2004","type":"journal-article","article-title":"Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein","volume":"78","author":"Giroglou","year":"2004","unstructured":"Giroglou, T. et al. Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein. J Virol. 78 (17), 9007-9015 (2004).","journal-title":"J Virol"},{"issue":"1","key":"ref20","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0168-1702(99)00070-2","type":"journal-article","article-title":"Murine leukemia virus pseudotypes of La Crosse and Hantaan bunyaviruses:A system for analysis of cell tropism","volume":"64","author":"Ma","year":"1999","unstructured":"Ma, M., Kersten, D. B., Kamrud, K. I., Wool-Lewis, R. J., Schmaljohn, C., Gonz\u00e1lez-Scarano, F. Murine leukemia virus pseudotypes of La Crosse and Hantaan bunyaviruses:A system for analysis of cell tropism. Virus Res. 64 (1), 23-32 (1999).","journal-title":"Virus Res"},{"issue":"23","key":"ref21","doi-asserted-by":"crossref","first-page":"11464","DOI":"10.1128\/JVI.75.23.11464-11473.2001","type":"journal-article","article-title":"Functional murine leukemia virus vectors pseudotyped with the visna virus envelope show expanded visna virus cell tropism","volume":"75","author":"Bruett","year":"2001","unstructured":"Bruett, L., Clements, J. E. Functional murine leukemia virus vectors pseudotyped with the visna virus envelope show expanded visna virus cell tropism. J Virol. 75 (23), 11464-11473 (2001).","journal-title":"J Virol"},{"issue":"7131","key":"ref22","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nature05539","type":"journal-article","article-title":"Transferrin receptor 1 is a cellular receptor for New World haemorrhagic fever arenaviruses","volume":"446","author":"Radoshitzky","year":"2007","unstructured":"Radoshitzky, S. R. et al. Transferrin receptor 1 is a cellular receptor for New World haemorrhagic fever arenaviruses. Nature. 446 (7131), 92-96 (2007).","journal-title":"Nature"},{"issue":"2","key":"ref23","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jviromet.2008.07.015","type":"journal-article","article-title":"Establishment of retroviral pseudotypes with influenza hemagglutinins from H1, H3, and H5 subtypes for sensitive and specific detection of neutralizing antibodies","volume":"153","author":"Wang","year":"2008","unstructured":"Wang, W. et al. Establishment of retroviral pseudotypes with influenza hemagglutinins from H1, H3, and H5 subtypes for sensitive and specific detection of neutralizing antibodies. J Virol Methods. 153 (2), 111-119 (2008).","journal-title":"J Virol Methods"},{"issue":"1","key":"ref24","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","type":"journal-article","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","unstructured":"Bulcha, J. T., Wang, Y., Ma, H., Tai, P. W. L., Gao, G. Viral vector platforms within the gene therapy landscape. Signal Transduct Target Ther. 6 (1), 53 (2021).","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"ref25","doi-asserted-by":"crossref","first-page":"e0052721","DOI":"10.1128\/JCM.00527-21","type":"journal-article","article-title":"Evaluation of cell-based and surrogate SARS-CoV-2 neutralization assays","volume":"59","author":"Sholukh","year":"2021","unstructured":"Sholukh, A. M. et al. Evaluation of cell-based and surrogate SARS-CoV-2 neutralization assays. J Clin Microbiol. 59 (10), e0052721 (2021).","journal-title":"J Clin Microbiol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"126993","DOI":"10.1016\/j.micres.2022.126993","type":"journal-article","article-title":"Application of pseudovirus system in the development of vaccine, antiviral-drugs, and neutralizing antibodies","volume":"258","author":"Xiang","year":"2022","unstructured":"Xiang, Q., Li, L., Wu, J., Tian, M., Fu, Y. Application of pseudovirus system in the development of vaccine, antiviral-drugs, and neutralizing antibodies. Microbiol Res. 258, 126993 (2022).","journal-title":"Microbiol Res"},{"issue":"21","key":"ref27","doi-asserted-by":"crossref","first-page":"e01062","DOI":"10.1128\/JVI.01062-20","type":"journal-article","article-title":"Optimized pseudotyping conditions for the SARS-CoV-2 spike glycoprotein","volume":"94","author":"Johnson","year":"2020","unstructured":"Johnson, M. C. et al. Optimized pseudotyping conditions for the SARS-CoV-2 spike glycoprotein. J Virol. 94 (21), e01062-20 (2020).","journal-title":"J Virol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"102125","DOI":"10.1016\/j.scr.2020.102125","type":"journal-article","article-title":"Neutralizing antibodies targeting SARS-CoV-2 spike protein","volume":"50","author":"Xiaojie","year":"2021","unstructured":"Xiaojie, S., Yu, L., Lei, Y., Guang, Y., Min, Q. Neutralizing antibodies targeting SARS-CoV-2 spike protein. Stem Cell Res. 50, 102125 (2021).","journal-title":"Stem Cell Res"},{"issue":"6515","key":"ref29","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1126\/science.abd9909","type":"journal-article","article-title":"De novo design of picomolar SARS-CoV-2 miniprotein inhibitors","volume":"370","author":"Cao","year":"2020","unstructured":"Cao, L. et al. De novo design of picomolar SARS-CoV-2 miniprotein inhibitors. Science. 370 (6515), 426-431 (2020).","journal-title":"Science"},{"issue":"4","key":"ref30","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.cell.2020.04.004","type":"journal-article","article-title":"Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2","volume":"181","author":"Monteil","year":"2020","unstructured":"Monteil, V. et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 181 (4), 905-913.e7 (2020).","journal-title":"Cell"},{"issue":"6","key":"ref31","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s41061-021-00353-7","type":"journal-article","article-title":"The repurposed ACE2 inhibitors:SARS-CoV-2 entry blockers of COVID-19","volume":"379","author":"Ahmad","year":"2021","unstructured":"Ahmad, I., Pawara, R., Surana, S., Patel, H. The repurposed ACE2 inhibitors:SARS-CoV-2 entry blockers of COVID-19. Top Curr Chem. 379 (6), 40 (2021).","journal-title":"Top Curr Chem"},{"issue":"1","key":"ref32","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41598-024-83637-4","type":"journal-article","article-title":"Discovering natural products as potential inhibitors of SARS-CoV-2 spike proteins","volume":"15","author":"Alqaaf","year":"2025","unstructured":"Alqaaf, M. et al. Discovering natural products as potential inhibitors of SARS-CoV-2 spike proteins. Sci Rep. 15 (1), 200 (2025).","journal-title":"Sci Rep"},{"issue":"9","key":"ref33","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1016\/j.apsb.2024.05.026","type":"journal-article","article-title":"Identification of novel small-molecule inhibitors of SARS-CoV-2 by chemical genetics","volume":"14","author":"Chan","year":"2024","unstructured":"Chan, C. C.-Y. et al. Identification of novel small-molecule inhibitors of SARS-CoV-2 by chemical genetics. Acta Pharm Sin B. 14 (9), 4028-4044 (2024).","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"ref34","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1038\/s41467-020-16048-4","type":"journal-article","article-title":"Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig","volume":"11","author":"Lei","year":"2020","unstructured":"Lei, C. et al. Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig. Nat Commun. 11 (1), 2070 (2020).","journal-title":"Nat Commun"},{"issue":"1","key":"ref35","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41421-020-0169-8","type":"journal-article","article-title":"The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro","volume":"6","author":"Wang","year":"2020","unstructured":"Wang, X. et al. The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro. Cell Discov. 6 (1), 28 (2020).","journal-title":"Cell Discov"},{"issue":"8","key":"ref36","doi-asserted-by":"crossref","first-page":"e984","DOI":"10.1002\/iid3.984","type":"journal-article","article-title":"Arbidol:The current demand, strategies, and antiviral mechanisms","volume":"11","author":"Kang","year":"2023","unstructured":"Kang, Y., Shi, Y., Xu, S. Arbidol:The current demand, strategies, and antiviral mechanisms. Immun Inflamm Dis. 11 (8), e984 (2023).","journal-title":"Immun Inflamm Dis"}],"container-title":["Journal of Visualized Experiments"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/app.jove.com\/t\/69628\/procedures-for-identification-sars-cov-2-entry-inhibitors-as","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:21:41Z","timestamp":1792588901000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jove.com\/t\/69628\/procedures-for-identification-sars-cov-2-entry-inhibitors-as"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":36,"journal-issue":{"issue":"228","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.3791\/69628","relation":{},"ISSN":["1940-087X"],"issn-type":[{"value":"1940-087X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]}}}